Crossmark

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis

Crossref DOI link: https://doi.org/10.1186/s13014-019-1235-y

Published Online: 2019-02-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Helfenstein, Seth

Riesterer, Oliver

Meier, Urs R.

Papachristofilou, Alexandros

Kasenda, Benjamin

Pless, Miklos

Rothschild, Sacha I. https://orcid.org/0000-0003-1304-9340
License Information

Text and Data Mining valid from 2019-02-11
More Information

Article History

Received: 29 November 2018

Accepted: 4 February 2019

First Online: 11 February 2019

Ethics approval and consent to participate

: This study was performed in accordance with institutional review board approval by the local ethical committees (ethical committee of northwestern and central part of Switzerland, (EKNZ) and cantonal ethical committee Zurich (KEK), approval number 2016–01062).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below